2. Search Result
Search Result
Results for "

Peptide inhibitors

" in MedChemExpress (MCE) Product Catalog:

1318

Inhibitors & Agonists

3

Screening Libraries

6

Fluorescent Dyes

25

Biochemical Assay Reagents

895

Peptides

2

MCE Kits

7

Inhibitory Antibodies

70

Natural
Products

25

Isotope-Labeled Compounds

10

Click Chemistry

1

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1740
    RGD peptide (GRGDNP)
    5+ Cited Publications

    		 Integrin Apoptosis Caspase Inflammation/Immunology
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP)
  • HY-P0301A
    SLLK, Control Peptide for TSP1 InhibitorTFA

    		TGF-β Receptor Cancer
    SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.
    SLLK, Control Peptide for TSP1 InhibitorTFA
  • HY-P5960
    PTBP1-RNA-binding inhibitor P6 TFA

    PTBP1 α3-helix derived Peptide P6 TFA

    		 DNA/RNA Synthesis Others
    PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .
    PTBP1-RNA-binding inhibitor P6 TFA
  • HY-P10000
    Peptide YY (PYY) (3-36), Human

    		Neuropeptide Y Receptor Metabolic Disease
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .
    Peptide YY (PYY) (3-36), Human
  • HY-P6437A
    Drp1 peptide inhibitor P110 TFA

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110 TFA
  • HY-P1741
    Fibrinogen-Binding Peptide
    1 Publications Verification

    		 Thrombin Cardiovascular Disease
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide
  • HY-P5910
    Azurin p28 peptide

    		MDM-2/p53 Apoptosis Cancer
    Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .
    Azurin p28 peptide
  • HY-P10950A
    PD-L1 inhibitory peptide TFA

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers .
    PD-L1 inhibitory peptide TFA
  • HY-P3695
    VSPPLTLGQLLS

    		FGFR Cancer
    VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
    VSPPLTLGQLLS
  • HY-P1369
    DynaMin inhibitory peptide, myristoylated
    1 Publications Verification

    		 Dynamin Neurological Disease
    DynaMin inhibitory peptide, myristoylated is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated is a membrane-permeant form of the peptide that prevents endocytosis .
    DynaMin inhibitory peptide, myristoylated
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD Peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-P10218A
    MANS peptide TFA
    1 Publications Verification

    		 MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-P10422A
    Multi-Leu peptide triacetate

    ML-Peptide, Multi-Leucine (ML)-Peptide triacetate

    		 Autophagy Cancer
    Multi-Leu peptide (ML-peptide) triacetate is a potent inhibitor of PACE4 (Ki=22 nM). Multi-Leu peptide triacetate can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide triacetate can be used to study the specific mechanism of PACE4 in the development of prostate cancer .
    Multi-Leu peptide triacetate
  • HY-P4123
    TAT (47-57) GGG-Cys(Npys)

    		MMP Cardiovascular Disease Inflammation/Immunology Cancer
    TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders .
    TAT (47-57) GGG-Cys(Npys)
  • HY-122543
    PPACK II diTFA

    		Kallikrein Cardiovascular Disease
    PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor .
    PPACK II diTFA
  • HY-P3244
    D-KLVFFA

    		Amyloid-β Neurological Disease
    D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC50 of 2.6 μM, that can be used in Alzheimer's disease study .
    D-KLVFFA
  • HY-P0301
    SLLK, Control Peptide for TSP1 Inhibitor

    		TGF-β Receptor Cancer
    SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
    SLLK, Control Peptide for TSP1 Inhibitor
  • HY-P10723
    IL-23R inhibitor peptide-1

    		Interleukin Related Inflammation/Immunology
    IL-23R inhibitor peptide-1 (comp 475) is an interleukin-23 receptor inhibitor, with an IC50 of 0.0069 μM .
    IL-23R inhibitor peptide-1
  • HY-103473A
    Boc-MLF TFA
    4 Publications Verification

    Boc-Met-Leu-Phe-OH TFA

    		 Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations .
    Boc-MLF TFA
  • HY-P10950
    PD-L1 inhibitory peptide

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
    PD-L1 inhibitory peptide
  • HY-P5786
    Heteropodatoxin-1

    HpTx1

    		 Potassium Channel Sodium Channel Neurological Disease
    Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8 .
    Heteropodatoxin-1
  • HY-P11300
    YKYY

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research .
    YKYY
  • HY-P11300A
    YKYY TFA

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    YKYY TFA is a blood pressure-lowering peptide isolated from the digest of Undaria pinnatifida. It is an angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY FTA can be used in hypertension research .
    YKYY TFA
  • HY-P11032
    Mp-4D7-pF2

    		SARS-CoV Virus Protease Infection
    Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
    Mp-4D7-pF2
  • HY-P10072A
    MK2-IN-5 acetate

    Hsp25 kinase inhibitor acetate; Mk2 pseudosubstrate acetate

    		 JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK Others
    MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation .
    MK2-IN-5 acetate
  • HY-P10485
    Glp-Asn-Pro-AMC

    		Thyroid Hormone Receptor Neurological Disease
    Glp-Asn-Pro-AMC is an inhibitor of thyrotropin-releasing hormone degrading enzyme (TRH-DE) with a Ki value of 0.97 μM .
    Glp-Asn-Pro-AMC
  • HY-P1190
    c-JUN peptide

    		JNK Apoptosis Inflammation/Immunology
    c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis .
    c-JUN peptide
  • HY-P5818
    BDS-II

    		Sodium Channel Neurological Disease
    BDS-II is a peptide toxin, and is composed of 43 amino acids. BDS-II is a selective Kv3.4 channel inhibitor .
    BDS-II
  • HY-161079
    TDI-8304

    		Parasite Infection
    TDI-8304, a macrocyclic peptide, is a potent, species selective, and noncovalent Plasmodium falciparum (Pf20S) inhibitor. TDI-8304 shows highly selective for Pf20S over human proteasomes .
    TDI-8304
  • HY-P1386
    D15

    Dynamin II (828–842)

    		 iGluR Neurological Disease
    D15, a peptide with 15 aa segment of dynamin, is an AMPAR endocytosis inhibitor. D15 blocks the interaction of dynamin with amphiphysin 1 and 2. D15 significantly increases AMPAR excitatory postsynaptic potential (EPSC) amplitude of medium spiny neurons (MSNs) in Sapap3 KO mice. D15 can be used for neuropsychiatric disorder research .
    D15
  • HY-P11224
    RMI-L4

    		DNA/RNA Synthesis Cancer
    RMI-L4 is an efficient cyclic peptide inhibitor that can specifically disrupt the interaction between FANCM and RMI proteins with an IC50 of 54 nM. RMI-L4 engages the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2.5 nM). RMI-L4 cannot penetrate the cell membrane and can be used to study the FANCM-RMI pathway targeting cancer with alternate lengthening of telomeres (ALT) .
    RMI-L4
  • HY-P3816
    PKCε Inhibitor Scramble Peptide

    		PKC Others
    PKCε Inhibitor Scramble Peptide is a scrambled peptide with identical amino acid composition to PKCε inhibitor peptide.
    PKCε Inhibitor Scramble Peptide
  • HY-P4133
    MEK1 Derived Peptide Inhibitor 1

    		ERK MEK Cancer
    MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by MEK1 with an IC50 value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .
    MEK1 Derived Peptide Inhibitor 1
  • HY-P3770
    Phosphate acceptor peptide

    		PKC Others
    Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .
    Phosphate acceptor peptide
  • HY-P1741A
    Fibrinogen-Binding Peptide TFA
    1 Publications Verification

    		 Integrin Cardiovascular Disease
    Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide TFA
  • HY-P5422
    Caloxin 3A1

    		Calcium Channel Others
    Caloxin 3A1 is a biological active peptide. (This peptide belongs to caloxins, the extracellular plasma membrane (PM) Ca2+ pump inhibitors. Caloxin 3A1 inhibits plasma membrane calcium pumps (PMCAs) but not the sarcoplasmic reticulum Ca2+-pump. This peptide does not inhibit formation of the acylphosphate intermediate from ATP.)
    Caloxin 3A1
  • HY-P5884A
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA

    		PKC Others
    PKCθ pseudosubstrate peptide inhibitor, myristoylated TFA is a synthetic peptide that can be used to study the mechanism of action of PKCθ .
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA
  • HY-P10422
    Multi-Leu peptide

    ML-Peptide, Multi-Leucine (ML)-Peptide

    		 Autophagy Cancer
    Multi-Leu peptide (ML-peptide) is a potent inhibitor of PACE4 (Ki=22 nM). Multi-Leu peptide can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide can be used to study the specific mechanism of PACE4 in the development of prostate cancer .
    Multi-Leu peptide
  • HY-P10818
    Polyglutamine binding peptide 1

    		Huntingtin Neurological Disease
    Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture .
    Polyglutamine binding peptide 1
  • HY-P11039
    IL-23 cyclic peptide inhibitor 281

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 281, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 281 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 281
  • HY-P11038
    IL-23 cyclic peptide inhibitor 105

    		Interleukin Related Inflammation/Immunology
    IL-23 cyclic peptide inhibitor 105, a cyclic peptide, is an IL-23 inhibitor. IL-23 cyclic peptide inhibitor 105 can be used for inflammatory disorders like inflammatory bowel disease (IBD) research .
    IL-23 cyclic peptide inhibitor 105
  • HY-P11006
    Onc112

    		Bacterial Infection
    Onc112 is a proline-rich antimicrobial peptide that displays potent activity against Gram-negative bacteria. Onc112 inhibits translation by blocking and destabilizing the initiation complex .
    Onc112
  • HY-P10974
    La peptide

    		HCV Enterovirus Infection
    La peptide (LAP) is an internal ribosome entry site (IRES) inhibitor. La peptide efficiently enters cells, blocks binding of cellular transacting factors to viral IRES, followed by inhibiting IRES-mediated translation. La peptide can be used for RNA viruses research, such as hepatitis C (HCV) and poliovirus (PV) .
    La peptide
  • HY-P60234A
    AGFAGDDAPR

    		Dipeptidyl Peptidase GLP Receptor Metabolic Disease
    AGFAGDDAPR is a bioactive peptide that is a competitive and orally effective inhibitor of dipeptidyl peptidase-IV (DPP-IV). AGFAGDDAPR can enhance the level of GLP-1 in the body by inhibiting DPP-IV, thereby stimulating insulin secretion, improving β-cell function, and inhibiting abnormal proliferation of α-cells, exerting anti-diabetic effects. AGFAGDDAPR can be used for research on type 2 diabetes .
    AGFAGDDAPR
  • HY-P11223
    CMF9

    		TGF-beta/Smad Inflammation/Immunology
    CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers α-SMA and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis .
    CMF9
  • HY-P10072
    MK2-IN-5

    Hsp25 kinase inhibitor; Mk2 pseudosubstrate

    		 ERK JNK p38 MAPK HSP MAPKAPK2 (MK2) Others
    MK2-IN-5 is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation .
    MK2-IN-5
  • HY-P3199
    PKCβII Peptide Inhibitor I

    		PKC Inflammation/Immunology
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
    PKCβII Peptide Inhibitor I
  • HY-122543A
    PPACK II

    		Kallikrein Cardiovascular Disease
    PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor .
    PPACK II
  • HY-P10517
    Sifuvirtide

    SFT

    		 HIV Infection
    Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
    Sifuvirtide
  • HY-P1376
    G-Protein antagonist peptide

    		mAChR Adrenergic Receptor Endocrinology
    G-Protein antagonist peptide is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors.
    G-Protein antagonist peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: